Brought to you by 
Lexicon Pharmaceuticals, Inc.
http://www.lexpharma.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lexicon Pharmaceuticals, Inc.
IPOs Are Back: Liquid Biopsy, Cardio, Dialysis Firms Lead $1.5Bn Charge
Who wants to go public during a once-in-a-century crisis? It seems like quite a few medtechs do.
Renalytix AI And AstraZeneca Collaborate To Improve Chronic Kidney Disease Outcomes
The companies will launch "precision medicine strategies" for chronic disease that use Renalytix' AI-enabled IVDs.
Renalytix AI Launches Trial To Identify COVID-19 Patients With Kidney Injury
The Mount Sinai spin-off believes its KindeyIntelX system can identify COVID-19 patients at high risk for long-term kidney damage.
Deal Watch: AbbVie Exits Inherited CRISPR-Cas9 Team-Up With Editas
Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools